Guggenheim Reiterates Buy Rating On Johnson & Johnson, Maintains $206 Price Target

Core Viewpoint - Guggenheim maintains a Buy rating and a price target of $206.00 on Johnson & Johnson, reflecting a positive outlook following a recent upgrade from Neutral [1] Group 1: Investor Sentiment - Investor feedback post-upgrade has been largely positive, with consensus that J&J shares are well positioned for further upside [2] - Analysts believe the company has effectively managed the initial impact of Stelara's loss of exclusivity and is entering a new growth phase supported by its Innovative Medicine segment [2] Group 2: Financial Adjustments - Guggenheim made minor adjustments to its financial model to reflect updated prescription and pricing data for key products, as well as recent foreign exchange fluctuations [3] - The firm anticipates potential upward revisions to earnings estimates and valuation multiples as the product cycle progresses [3]